Pharma Mar (PHME) Stock Overview

A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. More details

PHME fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	6/6
Past Performance	5/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 89.1% below our estimate of its fair value

Earnings are forecast to grow 39.64% per year

Earnings grew by 33.6% over the past year

Risk Analysis

Shares are highly illiquid

PHME Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW432,045 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

432,045 investors already sharing narratives

View all narratives

Pharma Mar, S.A. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pharma Mar
Historical stock prices
Current Share Price	€66.30
52 Week High	€104.80
52 Week Low	€66.30
Beta	0.43
1 Month Change	0%
3 Month Change	n/a
1 Year Change	-21.05%
3 Year Change	n/a
5 Year Change	-18.32%
Change since IPO	37.44%

Recent updates

Shareholder Returns

	PHME	GB Biotechs	GB Market
7D	0%	0.2%	-0.3%
1Y	-21.0%	-23.0%	15.8%

Return vs Industry: PHME exceeded the UK Biotechs industry which returned -23.1% over the past year.

Return vs Market: PHME underperformed the UK Market which returned 15.2% over the past year.

Price Volatility

Is PHME's price volatile compared to industry and market?
PHME volatility
PHME Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.9%
Market Average Movement	4.9%
10% most volatile stocks in GB Market	10.8%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: PHME's share price has been volatile over the past 3 months compared to the UK market.

Volatility Over Time: Insufficient data to determine PHME's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1986	505	Jose Fernandez Sousa-Faro	www.pharmamar.com

Pharma Mar, S.A., a biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally. It operates through Oncology and RNA Interference segments. The company offers Yondelis, a synthetic compound derived from the colonial sea squirt ecteinascidia turbinata that treats soft tissue sarcoma and ovarian cancer; Zepzelca, a synthetic compound designed to treat small lung cancer cells; and Aplidin, that is extracted from the ascidian Aplidium albicans to treat patients with multiple myeloma.

Pharma Mar, S.A. Fundamentals Summary

How do Pharma Mar's earnings and revenue compare to its market cap?
PHME fundamental statistics
Market cap	€1.33b
Earnings (TTM)	€56.13m
Revenue (TTM)	€218.64m

23.6x

P/E Ratio

6.1x

P/S Ratio

Is PHME overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PHME income statement (TTM)
Revenue	€218.64m
Cost of Revenue	€14.47m
Gross Profit	€204.17m
Other Expenses	€148.05m
Earnings	€56.13m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	3.24
Gross Margin	93.38%
Net Profit Margin	25.67%
Debt/Equity Ratio	17.2%

How did PHME perform over the long term?

See historical performance and comparison

Dividends

1.3%

Current Dividend Yield

32%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/09/13 21:23
End of Day Share Price	2026/06/16 00:00
Earnings	2026/06/30
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Pharma Mar, S.A. is covered by 12 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jaime Escribano	Banco Santander
Patricia Cifuentes	Bestinver Sociedad De Valores, S.A
Kambiz Yazdi	BTIG

Pharma Mar, S.A.BATS-CHIXE:PHME Stock Report